Intern Spotlight: Asya Akkus’ Journey on Battelle’s CBRNE Defense Team

Ever wondered what it’s really like to be an intern at Battelle? We asked Adam Helton, a third-year Ph.D. student in molecular genetics at The Ohio State University, to tell us about his experience firsthand. This summer, Adam is serving as a non-viral gene delivery intern, applying his academic expertise in a hands-on setting that’s shaping the future of gene therapy.

When Evie first walked through the doors of Battelle as a child during “Bring Your Child to Work Day,” she had no idea that years later she would return, not as a visitor, but as a valued member of the team.

The AFFF phase-out is gaining momentum across the United States, and industrial operators can't afford to ignore the shift. Here's what's driving the transition - and what it means for facilities still using Class B foams.

Gene therapy has come a long way in the last ten years. In the next decade, achieving efficiencies in its delivery will unlock its full potential.

In the European Union's stringent regulatory landscape, proactive compliance isn't just a necessity – it's a powerful strategic advantage. For plant protection product (PPP) companies, the upcoming re-registration process mandated by EU Regulation (EC) No 1107/2009, under Article 43, represents a critical juncture.